Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Table 3

Mutational analysis by ddPCR on FFPE biopsy and on ctDNA.

Relapsed Patients (UPN)	Target mutation selected by MPS			ddPCR ctDNA sampling
		Pretreatment	(T0)	3 months postsurgery	(T3)	Prerelapse	Relapse
1	TP 53 p.Tyr205Cys	Pos		Neg		Pos	Pos
6	PIK3CA p.His1047Arg	Pos		Neg		Neg	Neg
10	GATA3 p.Pro409fs	Pos		Neg		Neg	Neg
Nonrelapsed patients (UPN)	Target mutation selected by MPS	Pretreatment	(T0)	3 months postsurgery	(T3)	24 months postsurgery (T7)
2	PIK3CA p.Glu542Gly	Pos		Neg			Pos
4	TP 53 p.Trp53Thr	Neg		Neg			Pos